Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relaxin Therapy for Atrial Fibrillation
NCT07359872Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Dec 2030
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of Relaxin in Atrial fibrillation (AFib). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
Relaxin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07359872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07359872.